Valuation: TherapeuticsMD, Inc.

Market Cap 22.8M 19.96M 18.45M 17.02M 32.05M 2.19B 32.69M 220M 86.28M 1.07B 85.64M 83.74M 3.7B P/E 2024
-4.55x
P/E 2025 -30.9x
Enterprise Value 21.42M 18.75M 17.33M 15.99M 30.1M 2.06B 30.7M 207M 81.04M 1.01B 80.43M 78.65M 3.47B EV / Sales 2024
6.83x
EV / Sales 2025 5.78x
Free-Float
92.55%
Yield 2024 *
-
Yield 2025 -
1 day-0.60%
1 week+0.61%
Current month-13.99%
1 month+10.67%
3 months-4.60%
6 months-5.14%
Current year+22.06%
1 week 1.65
Extreme 1.65
1.69
1 month 1.51
Extreme 1.51
1.93
Current year 1.31
Extreme 1.31
2.3
1 year 1.31
Extreme 1.31
2.3
3 years 1.31
Extreme 1.31
2.3
5 years 0.11
Extreme 0.1051
45
10 years 0.11
Extreme 0.1051
383.75
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-29
Director of Finance/CFO 52 2023-08-16
Director TitleAgeSince
Director/Board Member 46 2012-02-28
Chairman 83 2012-04-15
Director/Board Member 69 2020-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+0.61% - - 22.8M
-2.62%-6.27%+44.35%+12.52% 306B
-0.25%-1.59%+26.99%-6.69% 69.32B
-1.39%-7.99%+30.18%+96.36% 9.03B
+1.16%-1.99%+7.49%+0.32% 8.48B
-5.93%-12.13%-21.97%-2.48% 4.16B
+8.22%+7.72%+20.08%+37.40% 4B
-2.06%-5.12%-40.13%+17.71% 3.4B
-1.46%-2.67%+37.40%+55.38% 2.75B
+1.57%+1.00%+10.61%-18.97% 2.15B
Average -0.05%-1.09%+12.78%+21.28% 45.51B
Weighted average by Cap. +0.13%-3.97%+38.50%+11.12%

Financials

2024 2025
Net sales 1.76M 1.54M 1.43M 1.31M 2.48M 169M 2.52M 17.01M 6.66M 82.78M 6.61M 6.47M 286M 3.02M 2.65M 2.45M 2.26M 4.25M 291M 4.33M 29.19M 11.44M 142M 11.35M 11.1M 490M
Net income -2.18M -1.91M -1.76M -1.63M -3.07M -210M -3.13M -21.07M -8.25M -103M -8.19M -8.01M -354M -569K -498K -460K -425K -800K -54.73M -816K -5.5M -2.15M -26.75M -2.14M -2.09M -92.29M
Net Debt 2.12M 1.85M 1.71M 1.58M 2.97M 204M 3.03M 20.44M 8.01M 99.46M 7.95M 7.77M 343M -1.39M -1.21M -1.12M -1.03M -1.95M -133M -1.99M -13.39M -5.24M -65.15M -5.21M -5.09M -225M
Logo TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Employees
1
Date Price Change
26-07-14 €1.660 -0.60%
26-07-13 €1.670 +1.21%
26-07-10 €1.650 0.00%
26-07-09 €1.650 -1.79%
26-07-08 €1.680 +1.82%